Clinical features and prognostic factors in adults with viral meningitis.
aseptic meningitis
herpesviridae
tick-borne encephalitis
toscana virus
virology
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
18
11
2022
revised:
08
02
2023
accepted:
25
02
2023
medline:
4
9
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Clinical features applicable to the entire spectrum of viral meningitis are limited, and prognostic factors for adverse outcomes are undetermined. This nationwide population-based prospective cohort study included all adults with presumed and microbiologically confirmed viral meningitis in Denmark from 2015 until 2020. Prognostic factors for an unfavourable outcome (Glasgow Outcome Scale score of 1-4) 30 days after discharge were examined by modified Poisson regression. In total, 1066 episodes of viral meningitis were included, yielding a mean annual incidence of 4.7 episodes per 100 000 persons. Pathogens were enteroviruses in 419/1066 (39%), herpes simplex virus type 2 in 171/1066 (16%), varicella-zoster virus in 162/1066 (15%), miscellaneous viruses in 31/1066 (3%) and remained unidentified in 283/1066 (27%). The median age was 33 years (IQR 27-44), and 576/1066 (54%) were females. In herpes simplex virus type 2 meningitis, 131/171 (77%) were females. Immunosuppression [32/162 (20%)] and shingles [90/149 (60%)] were frequent in varicella-zoster virus meningitis. The triad of headache, neck stiffness and hyperacusis or photophobia was present in 264/960 (28%). The median time until lumbar puncture was 3.0 h (IQR 1.3-7.1), and the median CSF leucocyte count was 160 cells/µl (IQR 60-358). The outcome was unfavourable in 216/1055 (20%) 30 days after discharge. Using unidentified pathogen as the reference, the adjusted relative risk of an unfavourable outcome was 1.34 (95% CI 0.95-1.88) for enteroviruses, 1.55 (95% CI 1.00-2.41) for herpes simplex virus type 2, 1.51 (95% CI 0.98-2.33) for varicella-zoster virus and 1.37 (95% CI 0.61-3.05) for miscellaneous viruses. The adjusted relative risk of an unfavourable outcome was 1.34 (95% CI 1.03-1.75) for females. Timing of acyclovir or valacyclovir was not associated with the outcome in meningitis caused by herpes simplex virus type 2 or varicella-zoster virus. In summary, the outcome of viral meningitis was similar among patients with different aetiologies, including those with presumed viral meningitis but without an identified pathogen. Females had an increased risk of an unfavourable outcome. Early antiviral treatment was not associated with an improved outcome in meningitis caused by herpes simplex virus type 2 or varicella-zoster virus.
Identifiants
pubmed: 36929167
pii: 7079005
doi: 10.1093/brain/awad089
pmc: PMC10473559
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3816-3825Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
J Meningitis. 2016 Jun;1(1):
pubmed: 27500284
Front Immunol. 2021 Aug 31;12:720952
pubmed: 34531867
Lancet Infect Dis. 2016 Mar;16(3):339-47
pubmed: 26652862
N Engl J Med. 2001 Dec 13;345(24):1727-33
pubmed: 11742046
Clin Infect Dis. 2013 Oct;57(8):1114-28
pubmed: 23861361
Infection. 2017 Apr;45(2):227-231
pubmed: 28236249
Scand J Infect Dis. 2008;40(1):59-62
pubmed: 17852910
J Med Virol. 2013 Mar;85(3):554-62
pubmed: 23239485
Infection. 2015 Aug;43(4):399-403
pubmed: 25956991
Antimicrob Agents Chemother. 2006 Jul;50(7):2409-14
pubmed: 16801419
QJM. 2010 Oct;103(10):749-58
pubmed: 20657024
Lancet Infect Dis. 2010 Dec;10(12):835-44
pubmed: 20952256
J Neurol. 2002 May;249(5):554-60
pubmed: 12021945
Neurology. 2006 Jan 10;66(1):75-80
pubmed: 16401850
Scand J Infect Dis. 2008;40(11-12):914-21
pubmed: 18615360
Clin Epidemiol. 2021 Oct 04;13:921-933
pubmed: 34675681
Sci Rep. 2019 Nov 6;9(1):16158
pubmed: 31695095
Clin Epidemiol. 2020 Jul 16;12:745-755
pubmed: 32765109
J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):554-8
pubmed: 16543543
Brain. 2006 Feb;129(Pt 2):333-45
pubmed: 16364957
Bioessays. 2012 Dec;34(12):1050-9
pubmed: 23012250
Clin Infect Dis. 2003 Dec 1;37(11):1527-33
pubmed: 14614676
Clin Infect Dis. 2022 Sep 14;75(5):753-760
pubmed: 34979025
Neurology. 2021 Aug 3;97(5):e454-e463
pubmed: 34088872
Lancet. 1975 Mar 1;1(7905):480-4
pubmed: 46957
J Infect Dis. 2020 Jul 23;222(4):619-627
pubmed: 32236420
J Med Virol. 2014 Oct;86(10):1766-71
pubmed: 25042344
Clin Infect Dis. 2015 Jan 15;60(2):237-42
pubmed: 25273082
Clin Microbiol Infect. 2017 Feb;23(2):121.e9-121.e15
pubmed: 27816734
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
N Engl J Med. 2004 Oct 28;351(18):1849-59
pubmed: 15509818
Nat Med. 2022 May;28(5):911-923
pubmed: 35585196
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Lancet Infect Dis. 2018 Sep;18(9):992-1003
pubmed: 30153934